Updates are available Correction dated 2023-01-19
Click to view Correction: https://doi.org/10.1038/s41467-023-35835-3
-
Authors
Chew, Kara W. https://orcid.org/0000-0003-4865-4348
Moser, Carlee https://orcid.org/0000-0001-5601-9112
Daar, Eric S.
Wohl, David A. https://orcid.org/0000-0002-7764-0212
Li, Jonathan Z. https://orcid.org/0000-0001-9914-9662
Coombs, Robert W. https://orcid.org/0000-0003-2709-0512
Ritz, Justin https://orcid.org/0000-0001-6307-4849
Giganti, Mark
Javan, Arzhang Cyrus
Li, Yijia
Choudhary, Manish C.
Deo, Rinki
Malvestutto, Carlos
Klekotka, Paul
Price, Karen
Nirula, Ajay
Fischer, William
Bala, Veenu
Ribeiro, Ruy M. https://orcid.org/0000-0002-3988-8241
Perelson, Alan S. https://orcid.org/0000-0002-2455-0002
Fletcher, Courtney V. https://orcid.org/0000-0002-3703-7849
Eron, Joseph J. https://orcid.org/0000-0002-4938-0644
Currier, Judith S. https://orcid.org/0000-0003-4279-4737
,
Hughes, Michael D.
Smith, Davey M. https://orcid.org/0000-0003-3603-1733
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UM1AI068636, UM1AI068634, UM1AI106701, R01AI028433)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (R01OD011095)
DOE | LDRD | Los Alamos National Laboratory (LDRD 20200743ER, 20200695ER, and 20210730ER)
- License Information
-
More Information
Article History
Received: 4 May 2022
Accepted: 4 August 2022
First Online: 22 August 2022
Change Date: 19 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-35835-3
Competing interests
: K.W.C. has received research funding to the institution from Merck Sharp & Dohme and is a consultant for Pardes Biosciences. E.S.D. receives consulting fees from Gilead Sciences, Merck, and GSK/ViiV and research support through the institution from Gilead Sciences and GSK/ViiV. D.A.W. has received funding to the institution to support research and honoraria for advisory boards and consulting from Gilead Sciences. J.Z.L. has consulted for Abbvie. C.M. has received research funding to the institution from E.L. P.K., K.P., and A.N. are employees and shareholders of E.L. W.F. has received research funding to the institution from Ridgeback Biopharmaceuticals, served on adjudication committees for Janssen, Syneos, and consulted for Roche and Merck. J.J.E. is an ad hoc consultant to GSK/VIR, data monitoring committee (DMC) chair for Adagio Phase III studies. J.S.C. has consulted for Merck and Company. D.M.S. has consulted for the following companies Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health and Brio Clinical. All other authors (R.C., C.M., J.R., M.G., A.C.J., Y.L., M.C.C., R.D., V.B., R.M.R., A.S.P., C.V.F., and M.D.H.) report no competing interests.
